Albine Martin

Executive in Residence

Johns Hopkins University and BioHealth Innovation

Dr. Albine Martin brings over 20 years of operating and product commercialization experience within 3 three public companies representing the biotechnology, diagnostics and life sciences sector.   She had provided translational leadership to advance technologies from bench to market during her role as  Executive in Residence at Johns Hopkins University and  Biohealth Innovation. As COO of Precision Biologics, (a clinical stage oncology company with a Companion Diagnostic)  she formulated a virtual business model and operationalized a network to advance biologics from preclinical to Phase 2 trials.  As Vice President at Compugen (CGEN), she built a consumable/data driven revenue model   and managed strategic alliances to advance both diagnostic and therapeutic candidates.   During her tenure at Life Technologies [LIFE] she was responsible for the global portfolio as   Senior Business Director and managed Joint Ventures and expansion within the Asia-Pacific region. She has collaborated with FDA/CBER to develop compliance standards and commercialization strategies for ancillary products within the Cellular Therapy arena. She was also part of the team that led the BLA approval and commercialization of the first HPV molecular diagnostic test commercialized by Digene Diagnostics.  She is a member of the NSF commercial reviewer panels for SIR 1/2 funding and MIT Enterprise Forum, Washington DC Chapter.   Dr. Martin holds a PhD from the University of Maryland and served as a Staff Fellow at the National Institutes of Health and holds a Certificate of Financial Management from Cornell University and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School.